Mineralys Therapeutics Inc (MLYS) News

Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024

RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage...

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

 – Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with...

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form 8-K - Current report

Mineralys Therapeutics Announces $120 Million Private Placement Financing

RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage...

Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage...

Form 8-K - Current report

Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage...

Form 8-K - Current report

Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 – – Topline data from ongoing...

Form 8-K - Current report

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence...

Mineralys Therapeutics to Participate in Three Upcoming Conferences

RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]